Difference between revisions of "International Federation of Pharmaceutical Manufacturers and Associations"
| Line 5: | Line 5: | ||
The IFPMA was created in 1968 in order to represent associations of international worldwide research-based pharmaceutical industry and manufacturers of prescribed medicines. | The IFPMA was created in 1968 in order to represent associations of international worldwide research-based pharmaceutical industry and manufacturers of prescribed medicines. | ||
| − | The conditions for membership of the Federation include to good manufacturing practices and acceptance of the IFPMA Code of Pharmaceutical Marketing Practices | + | The conditions for membership of the Federation include to good manufacturing practices and acceptance of the "IFPMA Code of Pharmaceutical Marketing Practices". |
| − | In November 2004, the IFPMA decided to make membership available to pharmaceutical companies, as long as these companies fulfil the conditions implied by the Federation’s objectives and mission. | + | In November 2004, the IFPMA decided to make membership available to pharmaceutical companies, as long as these companies fulfil the conditions implied by the Federation’s objectives and mission. [http://www.ifpma.org/About_Us/about_mission.aspx] |
| − | == | + | == Mission and objectives == |
| Line 71: | Line 71: | ||
== External links == | == External links == | ||
| + | |||
| + | * http://www.ifpma.org/index.aspx | ||
| + | * http://www.haiweb.org | ||
Revision as of 16:18, 22 April 2006
The IFPMA describes itself as a "non-profit, non-governmental organization representing industry associations from both developed and developing countries". [1] It is one of the main trade groups lobbying to establish 'public-private partnerships' between the private pharmaceutical industry and public health initiatives. [2]
History
The IFPMA was created in 1968 in order to represent associations of international worldwide research-based pharmaceutical industry and manufacturers of prescribed medicines. The conditions for membership of the Federation include to good manufacturing practices and acceptance of the "IFPMA Code of Pharmaceutical Marketing Practices". In November 2004, the IFPMA decided to make membership available to pharmaceutical companies, as long as these companies fulfil the conditions implied by the Federation’s objectives and mission. [3]
Mission and objectives
Individuals
IFPMA President
- Dr. Daniel Vasella, Chairman and Chief Executive Officer Novartis International AG
IFPMA Vice Presidents
- Dr. Henry A. McKinnell, Jr., Chairman and Chief Executive Officer Pfizer Inc.
- Haruo Naito, President and Chief Executive Officer Eisai Co. Ltd.
Directors
- Dr. Harvey E. Bale, Jr., Director General
- Dr. Odette Morin, Director, Regulatory and Scientific Affairs
- Dr. Eric Noehrenberg, Director, International Trade and Market Policy
- Dr. Ryoko Krause, Director, Biologicals and Vaccines
- Dr. Frédérique Santerre, Health Care Systems (ad-interim)
- Mr. Guy Willis, Director of Communications
- Mr. Takeshi Sano, Japan Liaison Executive
Members
Members are national or regional pharmaceutical industry associations in more than 60 countries and the following “research-based pharmaceutical, biotech, and vaccine companies”:
- Abbott Laboratories
- Akzo Nobel – Organon
- Almirall-Prodesfarma
- AstraZeneca
- Bayer
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Chugai Pharmaceutical
- Eisai
- Eli Lilly
- Esteve
- F-Hoffmann-La Roche
- Astellas Pharma Inc.
- GlaxoSmithKline
- Merck & Co., Inc.
- Menarini S.A.
- Merck KGaA
- Novartis International AG
- Pfizer
- Sanofi-Aventis
- Institut de Recherches Internationales Servier – I.R.I.S.
- Sigma-Tau
- Schering AG
- Schering-Plough
- Takeda
- Wyeth
